trafficking and processing of app a- and b -secretase
DESCRIPTION
Trafficking and processing of APP a- and b -secretase. Intracellular trafficking of APP: relation to its physiological function?. APP. TMD. 5A3/1G7. NH 2. APP localizes to the plasma membrane, Golgi and endosomes. Pastorino, unpublished data. APP. TMD. 5A3/1G7. NH 2. - PowerPoint PPT PresentationTRANSCRIPT
Trafficking and processing of APPand-secretase
Intracellular trafficking of APP: relation to its physiological
function?
APP
NH2
5A3/1G7TMD
APP localizes to the plasma membrane, Golgi and endosomes
Pastorino, unpublished data
COOH
APP
NH2
5A3/1G7TMD
APP internalizes from the plasma membrane into intracellular compartments, endosomes and Golgi
Koo and Squazzo, 1994
Protein trafficking and endocytosis
APP co-localizes with the endosomes
Pastorino et al., 2006
Because, the intracellular localization of APP INFLUENCES the production of Amyloid peptide
Why we want to study the trafficking of APP?
Processing of APP
-secretase
Protectivenon-amyloidogenic
pathway
Pathogenicamyloidogenic
pathway
APPTMD
sAPPs C83sAPPs
C99
-secretase
NH2 COOH
AAICDp3AICD
-secretase
-secretase-secretase
-secretase -secretase
Intracellular compartments and processing of APP
-secretase activity: in the plasma membrane (where metalloproteases, known to have like TACE and ADAM10/ADAM17, reside).
-secretase activity: mostly in the endosomes, possible also in the ER and Golgi
-secretase activity: mostly in the ER, also in lysosomes and possible at the plasma membrane (still under debate).
Trafficking of APP
-secretase activity
-secretase activity
-secretase activity
APP
C83
APP
C99
APPs
APP
AICD C99
A
APP retained @ plasma membrane =
Internalization of full length APP =
GOOD!!
BAD!!!
Protective non-amyloidogenic processing
pathogenic amyloidogenic processing
Products dowstream of non-amyloidogenic processing:
APPs: soluble stub of APP deriving from the -secretase cleavage : possible neurotrophic function
p3: c-terminal truncated portion of the sequence of b-amyloid, deriving from the subsequent action of - and -secretase. DOES NOT aggregate. Unknown function.
AICD: APP Intra Cellular Domain, deriving from the cleavage of -secretase. Known regulation of transcriptional activity.
Products downstream of the amyloidogenic processing:
APPs: soluble stub of APP deriving from the -secretase cleavage : unknown function
C99: c-terminal stub containing the entire intact sequence of the -amyloid peptide, deriving from the action of -secretase. It is the substrate from where -amyloid peptides derive.
-Amyloid peptides: generated by the subsequent action of - and -secretases. At very low concentration could be neurotrophic, however, when forming aggregates they are VERY TOXIC and lead to the formation of the core of the -amyloid plaque in AD
AICD: APP Intra Cellular Domain, deriving from the cleavage of -secretase. Known regulation of transcriptional activity.
Alpha-secretase: ADAM10, ADAM17, TACE
ADAM10 and ADAM17 expression: colocalization with APP and BACE
Higher expression in the brain
ADAM10’s expression profile is similar to the one of BACE and APP
ADAM10 and ADAM17 have a protective role: Implication in AD and cell growth
ADAM10 is essential for non-amyloidogenic processing of APP: Evidences in vitro
Characterization of ADAM10 transgenic mice
18 weeks old
ADAM10 regulates non-amyloidogenic APP processing in vivo
10 months old
ADAM10 protects from plaque deposition in APPTg V717I (Indiana) mice…
17-19 months old
…in an age-dependent fashion
ADAM10XAPPtg
ADAM10 DN XAPPtg
Overexpression of ADAM10 in double transgenic mice ADAM10 X APPV717I rescues behavioral impairment
Could ADAM10 levels decrease during aging causing AD?
Sirtuins levels are reduced in aging
DO sirtuins regulate ADAM10 expression and/or activity?
Sirtuin: deacetylation and control on protein transcription
SIRT1 Tg AD mice show reduced plaque and Abeta load
Sirt1 expression in AD miceregulates non-amyloidogenic processing of APP…
..and also levels of the -secretase ADAM10 in AD mice both as protein….
…and as mRNA
Loss of non-amyloidogenic activity as a possible way to develop AD?
Alzheimer’s pathology and depression
Selective Serotonin reuptake inhibitors (SSRI) reduce ISF Abeta…
…and activate protective pathways
Chronic SSRI treatment reduces the load of Abeta plaques in AD mice
4 months treatment
Chronic SSRI treatment reduces the load of Abeta peptides in AD mice…
…and increases alpha-secretase activity
Use of antidepressant associates with reduced PIB uptake in humans
Activation of serotoninergic receptors leads to increased non-amyloidogenic pathway
Activation of non-amyloidogenic pathway as protective from AD!
The aspartyl protease BACE -Amyloid cleaving enzyme
BACE is expressed mostly in the brain
Vassar et al., 1999
Vassar et al., 1999
In the cell, BACE localizes to Golgi apparatus and Endosomes
1-In vitro, BACE is mostly active at an acidic pH range between 4.5-5.5.
2-BACE is supposed to be mostly active in the endosomes, due to BACE co-localization and to the acidic pH of these organelles.
Although in vivo, interaction between BACE and APP was observed at the plasma membrane and in the endosomes, in cell culture, BACE was active also in the ER and in the Golgi apparatus.
BACE activity
BACE KO mice lack amyloidgenic processing of APP
Abeta levels are reduced in BACE KO mice
Levels of BACE protein are increased in AD
BACE enzymatic activity is increased in AD brain
BACE Domains and trafficking
TMPropeptidesequence DTG DSG
DDISLLKfurin
1 501aa460-476
Regulation of BACE Trafficking
Abeta?
The LL motif, but not the S (that can be phoshorylated) regulates the amount of BACE retained at the plasma membrane…..
Pastorino et al., MCN 2002
BACE LL motif determines lysosomal colocalization for degradation
Koh et al., 2005
GGA proteins: a crucial role in the regulation of BACE trafficking and degradation through BACE LL domain
Do GGA3 and BACE levels change during neurodegenerative pathologies?
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
Ischemic patients have increased levels of BACE in the brain…
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
…and decreased levels of GGA3
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
AD patients have increased levels of BACE and decreased levels of GGA3 in the brain…
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
GGA3 siRNA causes increase of BACE expression and accumulation of C99
What happens during apoptosis?
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
APP contains caspase cleavage sites in its sequence
However, although apoptosis increases C99 and A levels, this effects do not depend on caspase-mediated cleavage of APP (Tesco et al., 2003).
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
Apoptosis increases levels of C99…..
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
…and BACE
Tesco et al., Neuron. 2007 Jun 7;54(5):721-37.
During apoptosis GGA3 levels are destabilized
Apoptotic mechanisms associated with neurodegeneration stabilize BACE via the inhibition of GGA3, therefore inhibiting
GGA3-mediated BACE degradation
Vassar, Neuron. 2007 Jun 7;54(5):671-3. Review.
Model of BACE stabilization during apoptosis